Polymorphism of Baculoviral Inhibitor of Apoptosis Repeat-Containing 5 (BIRC5) Can Be Associated with Clinical Outcome of Non-Small Cell Lung Cancer

Non-small cell lung cancer (NSCLC) comprises about 85% of all lung cancers. Currently, NSCLC therapy is based on the analysis of specific predictors, whose presence qualifies patients for appropriate treatment. Baculoviral inhibitor of apoptosis repeat-containing 5 (BIRC5), also known as “survivin”,...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Michał Szczyrek, Radosław Mlak, Aneta Szudy-Szczyrek, Kamila Wojas-Krawczyk, Karolina Kędziora, Janusz Milanowski
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	MDPI AG 2022-03-01
Edice:	Cells
Témata:	BIRC5 Survivin NSCLC outcome
On-line přístup:	https://www.mdpi.com/2073-4409/11/6/956
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!